https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-01 / Life (Basel) 2023 Jul;13(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-01 / Life (Basel) 2023 Jul;13(7)2023-07-01 00:00:002023-07-01 00:00:00Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-11 / Prostate 2021 Nov;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-11 / Prostate 2021 Nov;2021-11-11 00:00:002021-11-11 00:00:00Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)2021-06-09 00:00:002021-06-09 00:00:00Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-29 / Front Immunol 2021;12:641307
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-29 / Front Immunol 2021;12:6413072021-03-29 00:00:002021-03-29 00:00:00Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-10-26 / Front Oncol 2020;10:536700
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-10-26 / Front Oncol 2020;10:5367002020-10-26 00:00:002020-10-26 00:00:00High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-01 / J Immunother Cancer 2020 03;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-01 / J Immunother Cancer 2020 03;8(1)2020-03-01 00:00:002022-09-29 14:17:36Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-4297
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-26 / J Cell Mol Med 2020 04;24(7):4286-42972020-02-26 00:00:002022-09-29 14:03:50Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e188892020-02-01 00:00:002020-02-01 00:00:00Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-14 / J Immunother Cancer 2019 Nov;7(1):3022019-11-14 00:00:002019-11-14 00:00:00Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO4352019-10-29 00:00:002019-10-29 00:00:00Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
